RxDoctor Payments Data

Swathi Chalasani, MD

Internal Medicine · Champaign, ILNPI 1528440757

Payments from drug & device makers

$4,234in general payments, 2019–2025

Across 239 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$944
  • UCB, Inc.$441
  • AbbVie$325
  • AstraZeneca$280
  • Genentech USA, Inc.$196
  • plus $653 from 15 others

What the payments were for

  • Food & beverage$4,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,234 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$462,784
Medicare patients
195
Services billed
38,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab125$1,169,687
Enbrel SureclickEtanercept31$238,737
Actemra ActpenTocilizumab57$211,108
Enbrel MiniEtanercept21$200,060
Taltz AutoinjectorIxekizumab14$138,244
Humira(Cf)Adalimumab12$82,557
OtezlaApremilast13$64,464
Orencia ClickjectAbatacept11$63,624
Hydroxychloroquine Sulfate301$15,145
MethotrexateMethotrexate Sodium228$8,533
RasuvoMethotrexate/Pf15$8,104
Colchicine50$3,279
Mycophenolate Mofetil36$2,488
Prednisone304$2,122
Leflunomide29$2,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$325$82,55712 claims
AmgenOtezla$1,395$64,46413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →